Clinical Trial Update: Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency [Phase 3]

View source ↗

Summary

Phase 3 trial update for ARALAST NP and GLASSIA in alpha-1 antitrypsin deficiency (A1PI) has terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Aralast NP (alpha1-antitrypsin)
• Glassia (alpha-1 proteinase inhibitor)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency | Phase 3 | Status: TERMINATED | Results posted: 2019-10-08